
Merck, Evidation to test if smartphone data can be used to detect early Alzheimer’s
Merck and Evidation Health launched a study to see if data from smartphones and wearables could be used to detect and monitor the treatment of Alzheimer’s Disease.
Merck and Evidation Health launched a study to see if data from smartphones and wearables could be used to detect and monitor the treatment of Alzheimer’s Disease.
Evidation, launched as a research app where people can opt into virtual clinical trials, now plans to offer digital health programs. The company recently raised $153 million in new funding.
Early results from a study conducted by Evidation Health, Eli Lilly and Apple have shown the ability to detect cognitive decline and mild Alzheimer’s disease using a combination of Apple wearables, mobile devices, digital apps and sleep sensors.
At the MedCity INVEST conference this week, panelists from a payer, private equity firm, accelerator and digital health validation group discussed what they look for in digital health startups and offered advice on selecting a partner.
Evidation Health does clinical validation of digital health tools to help payers, providers and health systems handle the tough job of sifting through them to identify which ones are most appropriate for their patients and members.
The interest in adopting digital health tools such as clinical wearables and smartphone diagnostics has been hindered in some ways by the rapid growth in the number of these devices and relatively little clinical validation. GE Ventures and Stanford Health Care have partnered to launch a company called Evidation Health to validate and optimize digital […]